The British Journal of Clinical Pharmacology

Volume 51
2001

Published for
The British Pharmacological Society by
Blackwell Science

© 2001 Blackwell Science Ltd
Osney Mead, Oxford OX2 0EL
25 John Street, London WC1N 2BL
23 Ainslie Place, Edinburgh EH3 6AJ
Commerce Place, 350 Main Street, Malden MA 02148-5018, USA
54 University Street, Carlton, Victoria 3053, Australia

Other Editorial Offices:
Blackwell Wissenschafts-Verlag GmbH
Kurfürstendamm 57
1707 Berlin
Germany

Blackwell Science KK
MG Kodenmacho Building
7–10 Kodenmacho Nihombashi
Chuo-ku, Tokyo 104
Japan

Published on behalf of
The British Pharmacological Society

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without the prior permission of the copyright owner. Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by Blackwell Science for libraries and other users registered with the Copyright Clearance Center (CCC) Transactional Reporting Service, provided that the base fee of $15.00 per copy is paid directly to CCC, 222 Rosewood Drive, Suite 910, Danvers, MA 01923, USA. 0206-5251/01 $15.00/0. (For copying beyond that permitted by Sections 107 or 108 of the US Copyright Law). This consent does not extend to other kinds of copying, such as copying for general distribution, for advertising or promotional purposes, for creating new collective works, or for resale. Special requests should be addressed to the Editor.

Typeset, Printed and Bound by The Charlesworth Group, Huddersfield

Contents

This article is considered particularly suitable for continuing medical education.

Volume 51, Number 1, January 2001

Editorial

1 Genes for common diseases: *M.J. Caulfield*

Review series

5 *Genes for common diseases edited by Prof. M.J. Caulfield*
The genetics of essential hypertension: *K.M. O'Shaughnessy*

Review

13 Drug treatment of obesity: from past failures to future successes?: *P. Collins & G. Williams*

Pharmacodynamics

27 Effect of dexmedetomidine, an α-2 agonist, on human pupillary reflexes during general anaesthesia: *M.D. Larson & P.O. Talke*

35 Pharmacodynamic models for the cardiovascular effects of moxonidine in patients with congestive heart failure: *L. Brynne, J.L. McNay, H.G. Schaefer, K. Swedberg, C.G. Wiltse & M.O. Karlsson*

Drug disposition

45 Potent inhibition of CYP2D6 by haloperidol metabolites: stereoselective inhibition by reduced haloperidol: *J.-G. Shin, K. Kane & D.A. Flockhart*

53 *Trans*-3′-hydroxycontinine: disposition kinetics, effects, and plasma levels during cigarette smoking: *N.L. Benowitz & P. Jacob III*

Population pharmacokinetics

61 Population pharmacokinetics of thioTEPA and its active metabolite TEPA in patient undergoing high-dose chemotherapy: *A.D.R. Huitema, R.A.A. Mathôt, M.M. Tibben, J.H.M. Schellens, S. Rodenhuis & J.H. Beijnen*

71 Population modelling of the effect of inogatran, at thrombin inhibitor, on *ex vivo* coagulation time (aptt) in healthy subjects and patients with coronary artery disease: *M. Cullberg, U.G. Eriksson, M. Larsson & M.O. Karlsson*

Adverse drug reactions

81 Attitudes of hospital pharmacists to adverse drug reaction reporting: *C.F. Green, D.R. Mottram, P.H. Rowe & M. Pirmohamed*

87 Risk factors in the development of adverse reactions to *N*-acetylcysteine in patients with paracetamol poisoning: *L.E. Schmidt & K. Dalhoff*

Drug utilization

93 Co-prescribing of ssris & tcas in Australia: how often does it occur and who is doing it?: *P. McManus, A. Mant, P. Mitchell, D. Birkett & J. Dudley*

Short reports

99 Effect of α_1-acid glycoprotein on the intracellular accumulation of the hiv protease inhibitors saquinavir, ritonavir and indinavir *in vitro*: *K. Jones, P.G. Hoggard, S. Khoo, B. Maher & D.J. Back*

103 Systemic bioavailability of fluticasone propionate administered as nasal drops and aqueous nasal spray formulation: *P.T. Daley-Yates & R.C. Baker*

Letter to the Editors

107 Terbinafine-associated inhibition on the dextromethorphan metabolism in Chinese subjects: *W.M. Cai, B. Chen, S.S. Ling & Y.D. Zhang*

109 **Announcements**

Volume 51, Number 2, February 2001

Commentary

111 Journal impact factors: a 'bioequivalence' issue?: *A. Rostami-Hodjegan & G.T. Tucker*

Review

119 Biomarkers for the effects of antipsychotic drugs in healthy volunteers: *S.J. de Visser, J. van der Post, M.S.M. Pieters, A.F. Cohen & J.M.A. van Gerven*

Drug disposition

133 Involvement of human cytochromes P450 in the liver microsomal metabolism of astemizole and a comparison with terfenadine: *S. Matsumoto & Y. Yamazoe*

143 Disposition and metabolism of the flavonoid chrysin in normal volunteers: *T. Walle, Y. Otake, J.A. Brubaker, U.K. Walle & P.V. Halushka*

Drug interaction

147 The effects of lacidipine on the steady/state plasma concentrations of simvastatin in healthy subjects: *L. Ziviani, L. Da Ros, L. Squassante, S. Milleri, M. Cugola & L.E. Iavarone*

Pharmacoepidemiology

153 Effect of diuretics on fetal growth: A drug effect or confounding by indication? Pooled Danish and Scottish cohort data: *C. Olesen, C.S. de Vries, N. Thrane, T.M. MacDonald, H. Larsen, H.T. Sørensen & The EuroMAP Group*

Short reports

159 Nasal retention of budesonide and fluticasone in man: Formation of airway mucosal budesonide-esters *in vivo*: *H. Petersen, A. Kullberg, S. Edsbäcker & L. Greiff*

164 Pharmacokinetics of sabeluzole and dextromethorphan oxidation capacity in patients with severe hepatic dysfunction and healthy volunteers: *G.P. Pageaux, J. Micallef, M. Barugola Nataf, J.C. Levron, B. Lacarelle, J.P. Le Moing, P. Bouhours & O. Blin*

169 Influence of gender and oral contraceptives on CYP2D6 and CYP2C19 activity in healthy volunteers: *S. Hägg, O. Spigset & R. Dahlqvist*

174 Acetysalicylic acid and other salicylates in relation to Stevens-Johnson syndrome and toxic epidermal necrolysis: *D.W. Kaufman & J.P. Kelly for the International Case-Control Study of Severe Cutaneous Adverse Reactions*

177 Population pharmacokinetics of anti fibroblast activation protein monoclonal antibody F19 in cancer patients: *P. Tanswell, P. Garin-Chesa, W.J. Rettig, S. Welt, C.R. Divgi, E.S. Casper, R.D. Finn, S.M. Larson, L.J. Old & A.M. Scott*

181 Prescribing patterns in patients using new antidepressants: *W.E.E. Meijer, E.R. Heerdink, L.P. Pepplinkhuizen, J.T. van Eijk & H.G.M. Leufkens*

184 Prescribers prefer people: The sources of information used by doctors for prescribing suggest that the medium is more important than the message: *P. McGettigan, J. Golden, J. Fryer, R. Chan & J. Feely*

Letters to the Editors

191 The pharmacokinetics of etanercept in patients with heart failure: *O. Soran, A.M. Feldman, V.M. Schneider, R. Hanna, D.L. Mann & J.M. Korth-Bradley*

192 Non-responders in clinical pharmacology – a commentary to a book review by D.N. Bateman: *F. Sjöqvist*

Book Review

194 Fundamentals of Psychoneuroimmunology: *C.M. Pariante*

Volume 51, Number 3, March 2001

Review Series

195 *Genes for common diseases edited by Prof. M.J. Caulfield*
The genetics of type 2 diabetes: *M. McCarthy & S. Menzel*

Review

201 Anti-TNF agents for rheumatoid arthritis: *H.E. Seymour, A. Worsley, J.M. Smith & S.H.L. Thomas*

Meeting report

209 New insights into drug metabolism and toxicology Report of a symposium on drug metabolism and toxicity held at the British Pharmacological Society Meeting in Cardiff, UK, in July 2001: *M. A. Shaw*

Pharmacokinetics

213 The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz: *S.M. Clarke, F.M. Mulcahy, J. Tjia, H.E. Reynolds, S.E. Gibbons, M.G. Barry & D.J. Back*

Pharmacodynamics

219 Responsiveness of human varicose saphenous veins to vasoactive agents: *F. Brunner, C. Hoffmann & S. Schuller-Petrovic*

225 Assessment of forearm vasodilator responses to acetylcholine and albuterol by strain gauge plethysmography: reproducibility and influence of strain gauge placement: *H.A. Walker, G. Jackson, J.M. Ritter & P.J. Chowienczyk*

Pharmacokinetics/pharmacodynamics

231 Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation: *D.R. Abernethy, D.L. Wesche, J.T. Barbey, C. Ohrt, S. Mohanty, J.C. Pezzullo & B.G. Schuster*

Drug disposition

239 Identification in the cytochrome P450 enzymes involved in the *N*-demethylation of sildenafil: *R. Hyland, E.G.H. Roe, B.C. Jones & D.A. Smith*

Drug interaction

249 Evaluation of a pharmacokinetic interaction between remacemide hydrochloride and phenobarbitone in healthy males: *W.D. Hooper, M.J. Eadie, G.E. Blakey, J.A. Lockton & M. Manun'Ebo*

Drug utilization

257 Outcomes of a randomized controlled trial of a clinical pharmacy intervention in 52 nursing homes: *M.S. Roberts, J.A. Stokes, M.A. King, T.A. Lynne, D.M. Purdie, P.P. Glaszion, D.A.J. Wilson, S.T. McCarthy, G.E. Brooks, F.J. de Looze & C.B. Del Mar*

267 Patterns of prescription and drug use in ophthalmology in a tertiary hospital in Delhi: *N.R. Biswas, S. Jindal, M.M. Siddiquei & R. Maini*

Pharmacoepidemiology

271 Sudden unexpected death in infants under 3 months of age and vaccination status – a case-control study: *A.-P. Jonville-Béra, E. Autret-Leca, F. Barbeillon, J. Paris-Llado & the French Reference Centres for SIDS*

Short reports

277 Frequency of cytochrome P450 2C9 mutant alleles in a Korean population: *Y.-R. Yoon, J.-H. Shon, M.-K. Kim, Y.-C. Lim, H.-R. Lee, J.-Y. Park, I.-J. Cha & J.-G. Shin*

281 Involvement of human liver cytochrome P4502B6 in the metabolism of propofol: *Y. Oda, N. Hamaoka, T. Hiroi, S. Imaoka, I. Hase, K. Tanaka, Y. Funae, T. Ishizaki & A. Asada*

Volume 51, Number 4, April 2001

Editorial

287 Research methods in human respiratory pharmacology: *A.H. Morice*

Review series

289 Methods to identify drug deposition in the lungs following inhalation: *H. Chrystyn*

Therapeutic drug monitoring

301 The role of therapeutic drug monitoring in treatment of HIV infection: *D.J. Back, S.H. Khoo, S.E. Gibbons & C. Merry*

Pharmacokinetics/pharmacodynamics

309 Lack of effect of ondansetron on the pharmacokinetics and analgesic effects of morphine and metabolites after single-dose morphine administration in healthy volunteers: *K.R. Crews, B.P. Murthy, E.K. Hussey, A.N. Passannante, J.L. Palmer, W. Maixner & K.L.R. Brouwer*

Pharmacodynamics

317 Dose requirement and prolactin elevation of antipsychotics in male and female patients with schizophrenia or related psychoses: *K.I. Melkersson, A.-L. Hulting & A.J. Rane*

325 A randomized controlled assessment of the effects of different dosing regimens of budesonide on the HPA-axis in healthy subjects: *N. Andersson, A. Källén & L. Thorsson*

329 A placebo-controlled study examining the effect of allopurinol on heart rate variability and dysrhythmia counts in chronic heart failure: *A.M.A. Shehab, R. Butler, R.J. MacFadyen & A.D. Struthers*

335 A dose-response study of adrenaline combined with lignocaine 2%: effect on acute postoperative pain after oral soft tissue surgery: *L. Jorkjend & L.A. Skoglund*

Short reports

342 Drug expenditure in hospitals: what do German ward physicians know?: *J.U. Schnurrer, D.O. Stichtenoth, R. Troost & J.C. Frölich*

345 Carbamazepine is not a substrate for P-glycoprotein: *A. Owen, M. Pirmohamed, J.N. Tettey, P. Morgan, D. Chadwick & B.K. Park*

350 A single dose of methadone inhibits cytochrome P-4503A activity in healthy volunteers as assessed by the urinary cortisol ratio: *D.W. Boulton, P. Arnaud & C.L. DeVane*

355 Effects of nociceptin and endomorphin 1 on the electrically stimulated human vas deferens: *R. Bigoni, G. Calo, R. Guerrini, J.W. Strupish, D.J. Rowbotham & D.G. Lambert*

359 Pharmacokinetics and systemic β_2-adrenoceptor-mediated responses to inhaled salbutamol: *S.J. Fowler & B.J. Lipworth*

363 **Proceedings of the British Pharmacological Society, Clinical Pharmacology Section, University of Birmingham, 18–21 December 2000**

Volume 51, Number 5, May 2001

Editorial

393 Interim analyses in clinical trials: *J. Whitehead, S. Todd, A. Whitehead & N. Stallard*

Review series

394 Interim analyses and sequential designs in phase III studies: *S. Todd, A. Whitehead, N. Stallard & J. Whitehead*

Pharmacokinetics

400 Beclomethasone dipropionate: absolute bioavailability, pharmacokinetics and metabolism following intravenous, oral, intranasal and inhaled administration in man: *P.T. Daley-Yates, A.C. Price, J.R. Sisson, A. Pereira & N. Dallow*

410 Influence of cirrhosis on lamotrigine pharmacokinetics: *P. Marcellin, F. de Bony, C. Garret, C. Altman, V. Boige, C. Castelnau, P. Laurent-Puig, J.C. Trinchet, P. Rolan, C. Chen, J.P. Mamet & R. Bidault*

Pharmacodynamics

415 Dopamine D_2-like receptors and amino acid-induced glomerular hyperfiltration in humans: *G. Luippold, S. Schneider, A. Stefanescu, P. Benöhr & B. Mühlbauer*

Pharmacokinetics/pharmacodynamics

423 Concentration-effect relationships of two infusion rates of the imidazoline antihypertensive agent rilmenidine for blood pressure and development of side-effects in healthy subjects: *S.J. de Visser, J.M.A. van Gerven, R.C. Schoemaker & A.F. Cohen*

Drug interactions

429 The effect of anastrozole on the single-dose pharmacokinetics and anticoagulant activity of warfarin in healthy volunteers: *R.A. Yates, J. Wong, M. Seiberling, M. Merz, W. März & M. Nauck*

437 Effect of MAO-A inhibition on the pharmacokinetics of almotriptan, an antimigraine agent in humans: *J.C. Fleishaker, K.K. Ryan, J.M. Jansat, B.J. Carel, D.J.A. Bell, M.T. Burke & N.E. Azie*

443 Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects: *B. Lebrun-Vignes, V. Corbrion Archer, B. Diquet, J.C. Levron, O. Chosidow, A.J. Puech & D. Warot*

Drug disposition

451 Enterocytic CYP3A4 in a paediatric population: developmental changes and the effect of coeliac disease and cystic fibrosis: *T.N. Johnson, M.S. Tanner, C.J. Taylor & G.T. Tucker*

461 Inhibitory effects of verapamil and diltiazem on simvastatin metabolism in human liver microsomes: *K.R. Yeo & W.W. Yeo*

Short reports

471 Mephenytoin as a probe for CYP2C19 phenotyping: effect of sample storage, intra-individual reproducibility and occurrence of adverse events: *W.J. Tamminga, J. Wemer, B. Oosterhuis, J. Wieling, D.J. Touw, R.A. de Zeeuw, L.F.M.H. de Leij & J.H.G. Jonkman*

475 Frequencies of thiopurine S-methyltransferase mutant alleles (*TPMT*2, *3A, *3B and *3C*) in 151 healthy Japanese subjects and the inheritance of *TPMT*3C* in the family of a propositus: *T. Kubota & K. Chiba*

478 Quinapril and its metabolite quinaprilat in human milk: *E.J. Begg, R.A. Robson, S.J. Gardiner, L.J. Hudson, P.A. Reece, S.C. Olson, E.L. Posvar & A.J. Sedman*

482 Influence of ACE-inhibition on salt-mediated worsening of pulmonary gas exchange in heart failure: *M. Guazzi, R. Brambilla, P. Agostoni & M.D. Guazzi*

Letter to the Editors

489 Hepatitis B vaccine and first episodes of central nervous system demyelinating disorders: a comparison between reported and expected number of cases: *A. Fourrier, B. Bégaud, A. Alpérovitch, M.-H. Verdier-Taillefer, E. Touzé, N. Decker & J.-L. Imbs*

Book reviews

491 A textbook of clinical pharmacology: *G.A. Ford*

491 Drug interactions and infectious diseases: *G.M. Shenfield*

493 **Proceedings of the Dutch Society for Clinical Pharmacology and Biopharmacy, 2 October 2000**

Volume 51, Number 6, June 2001

Review series

507 *Research Methods in Human Cardiovascular Pharmacology edited by Dr S. Maxwell and Prof. D. Webb.* Pulse wave analysis: *M.F. O'Rourke, A. Pauca & X.-J. Jiang*

523 Stopping rules for phase II studies: *N. Stallard, J. Whitehead, S. Todd & A. Whitehead*

Pharmacokinetics

531 6-Thioguanine in children with acute lymphoblastic leukaemia: influence of food on parent drug pharmacokinetics and 6-thioguanine nucleotide concentrations: *D.L. Lancaster, N. Patel, L. Lennard & J.S. Lilleyman*

541 Oral bioavailability of dihydroartemisinin in Vietnamese volunteers and in patients with falciparum malaria: *T.Q. Binh, K.F. Ilett, K.T. Batty, T.M.E. Davis, N.C. Hung, S.M. Powell, L.T.A. Thu, H.V. Thien, H.L. Phuông & V.D.B. Phuong*

547 Simultaneous administration of a cocktail of markers to measure renal drug elimination pathways: absence of a pharmacokinetic interaction between fluconazole and sinistrin, *p*-aminohippuric acid and pindolol: *A.S. Gross, A.J. McLachlan, I. Minns, J.B. Beal & S.E. Tett*

Population pharmacokinetics

557 Increased oral ganciclovir bioavailability in HIV-infected patients with chronic diarrhoea and wasting syndrome—a population pharmacokinetic study: *S. Mouly, G. Aymard, J.-P. Tillement, C. Caulin, J.-F. Bergmann & S. Urien*

567 Population pharmacokinetics of carbamazepine in Singapore epileptic patients: *E. Chan, H.S. Lee & S.S. Hue*

Pharmacodynamics

577 Platelet CD62 expression and $PDGF_{AB}$ secretion in patients undergoing PTCA and treatment with abciximab: *J. Graff, D. Andries, M. Elsner, D. Westrup, S. Bassus, N. Franz, U. Klinkhardt & S. Harder*

583 Comparison of the effects of nadolol and bisoprolol on the isoprenaline-evoked dilatation of the dorsal hand vein in man: *A.H. Abdelmawla, R.W. Langley, E. Szabadi & C.M. Bradshaw*

Drug interactions

591 Pharmacokinetic interaction between mefloquine and ritonavir in healthy volunteers: *Y. Khaliq, K. Gallicano, C. Tisdale, G. Carignan, C. Cooper & A. McCarthy*

Pharmacovigilance

601 Public health impact of adverse bone effects of oral corticosteroids: *T.P. van Staa, L. Abenhaim, C. Cooper, B. Zhang & H.G.M. Leufkens*

609 A 6-month large-scale study into the safety of tamsulosin: *M.C. Michel, H.-U. Bressel, M. Goepel & H. Rübben*

Drug utilization

615 Drug therapy in the elderly: what doctors believe and patients actually do: *I. Barat, F. Andreasen & E.M.S. Damsgaard*

Short reports

623 Recording previous adverse drug reactions—a gap in the system: *G.M. Shenfield, T. Robb & M. Duguid*

627 Is cytochrome P450 *2C9* genotype associated with NSAID gastric ulceration?: *J.H. Martin, E.J. Begg, M.A. Kennedy, R. Roberts & M.L. Barclay*

631 The effect of fluconazole on ritonavir and saquinavir pharmacokinetics in HIV-1-infected individuals: *C.H.W. Koks, K.M.L. Crommentuyn, R.M.W. Hoetelmans, D.M. Burger, P.P. Koopmans, R.A.A. Mathôt, J.W. Mulder, P.L. Meenhorst & J.H. Beijnen*

637 Indices for Volume 51